What Comes Next for Clinical Trials? Mukhtar Ahmed Says “Personalized Research”
Mukhtar Ahmed discusses how AI, real-world data, and federated analytics could accelerate the shift to personalized research.
Mukhtar Ahmed discusses how AI, real-world data, and federated analytics could accelerate the shift to personalized research.
BC Platforms has been recognized by Pharma Tech Outlook Europe for leadership in evidence generation and AI-enabled drug development.
A new opinion piece by Narasimha Kumar, published in MedCity News, explores why “AI in Drug Development Is Not a Data Problem, It’s an Evidence Problem.” The article examines how the challenge is no longer collecting data, but preserving the context, meaning, and relationships that transform data into usable evidence. Kumar argues that AI cannot
AI readiness in pharma depends on data, not just AI. Read how real‑world data and interoperability enable scalable evidence generation.
Federated learning with the Flower Framework is available within BC Platforms’ trusted research environments.
BC Platforms signs a Strategic Collaboration Agreement with AWS to scale secure, AI-powered research environments.
A closer look at how RWD, analytics, and AI are reshaping standard of care insights and evidence generation across the drug lifecycle.
BC Platforms earns the SEF.Growth High‑Potential label for secure, scalable innovation in health data.
NVIDIA accelerated computing now available in BC Mosaic TRE, delivering up to 80x faster analytics across multi-modal health data.
For press and media inquiries, contact our communications team at media@bcplatforms.com.
For partnerships, business opportunities, and all other inquiries, please fill out this form